SEC Form 4 · accession 0000899243-18-027475

LogicBio Therapeutics, Inc. · LOGC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 23, 2018

Accepted (ET)

Oct 25, 2018 · 6:24 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001664106

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Oct 23, 2018	C	2,997,760	—	A	2,997,760	I	See Footnote
Common Stock^F3	Oct 23, 2018	P	490,000	$10.00	A	3,487,760	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Convertible Preferred Stock^F3,F2	—	Oct 23, 2018	C	2,678,571	D	—	—	Common Stock	1,402,444	0	I
Series B Convertible Preferred Stock^F3,F2	—	Oct 23, 2018	C	3,046,943	D	—	—	Common Stock	1,595,316	0	I

F1The total represents shares received upon conversion of Series A and Series B Convertible Preferred Stock.
F2Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock.
F3The Reporting Person is an employee of OrbiMed Advisors Israel II Limited ("OrbiMed Limited"), which is the managing member of OrbiMed Israel GP II, L.P. ("OIP GP"). OIP GP is the general partner of OrbiMed Israel Partners II, L.P. ("OIP II"), the direct beneficial owner of these securities. By virtue of such relationships, OIP GP and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest.